Research Article

Long Noncoding RNA SNHG16 Regulates the Growth of Human Lung Cancer Cells by Modulating the Expression of Aldehyde Dehydrogenase 2 (ALDH2)

Yan Li, Lifeng Jiang, Zhaocheng Zhu, Binfan Fu, Xu Sun, and Yue Jiao

Department of Integrated Traditional Chinese-Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China 450008

Correspondence should be addressed to Lifeng Jiang; lifengjiang57@yahoo.com

Received 2 October 2021; Revised 14 January 2022; Accepted 13 April 2022; Published 20 May 2022

Academic Editor: Weiren Luo

Copyright © 2022 Yan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The involvement of long noncoding RNA (lncRNA) SNHG16 has been reported in several human cancers. Notwithstanding, the role of lncRNA SNHG16 is yet largely unknown in human lung cancer. Consequently, this study was undertaken to investigate the role and therapeutic potential of SNHG16 in human lung cancer. The results showed a significant ($P < 0.05$) transcriptional upregulation of SNHG16 in lung cancer tissues and cell lines. However, downregulation of SNHG16 resulted in significant ($P < 0.05$) inhibition of lung cancer A549 and SK-LU-1 cell proliferation. DAPI and annexin V/PI assays revealed apoptosis to be responsible for inhibition of cell proliferation and colony formation observed upon SNHG16 knockdown. This was accompanied by enhancement of Bax and suppression of Bcl-2 expression in A549 and SK-LU-1 cells. Transwell assays revealed that silencing of SNHG16 also significantly ($P < 0.05$) inhibited migration and invasion of A549 and SK-LU-1 cells. Bioinformatic analysis revealed that SNHG16 interacted with ALDH2 to exert its effects in human lung cancer cells. The expression of ALDH2 was found to be significantly ($P < 0.05$) suppressed in human lung cancer tissues and cell lines. Overexpression of ALDH2 inhibited the proliferation and colony formation of the A549 and SK-LU-1 cells. However, silencing of ALDH2 could avoid the tumor-suppressive effects of SNHG16 knockdown. Finally, SNHG16 silencing was also found to inhibit in vivo tumor growth. Collectively, the study unveils the molecular role of SNHG16 in regulating the development of lung cancer by interacting with ALDH2.

1. Introduction

Lung cancer is one of prevalent and most fatal human cancers responsible for the highest number of cancer-related deaths at the global level [1]. In 2020 alone, about 0.116 million men and 0.112 million women were affected by lung cancer, and more than 0.13 million patients died from the underlying malignancy in the United States [2]. At present, approximately 8.2 million deaths are believed to result from lung cancer annually, and the figures are alarmingly suggested to approach the 10 million per annum mark by 2030 [3]. The figures thus suggest the inefficiency of the presently opted anticancer measures against the malignancy of lung cancer and emphasize the necessity of exploring the alternative treatment measures which could help in restricting the lethality of lung cancer more effectively. The advancement in the sequencing techniques and microarray analysis along with the availability of diversity of bioinformatics software tools has been shown that more than 90% of human genome does not code for proteins although it is actively transcribed into RNA species called noncoding RNAs [4, 5]. Falling in the latter category, the long noncoding RNAs (lncRNAs) are greater than 200 nucleotides in length and help in gene regulation at transcriptional or posttranscriptional level depending on subcellular localization of lncRNAs [6]. Interestingly, the lncRNA dysregulation has been shown to be linked to a number of human cancers [7–9]. Also, a vast number of lncRNAs have been found to be differentially expressed in lung cancer tissues when compared to normal lung tissue samples implying their probable
involvement in lung cancer growth and development [10–12]. The recently identified lncRNA, small nucleolar RNA host gene 16 (SNHG16), has been found to be involved in the progression of number of human cancers like colon and cervical cancers [13, 14]. LncRNA SNHG16 has also been found to be involved in the development of lung cancer. For instance, increased expression of SNHG16 has been shown to be associated with poor prognosis of lung cancer [15]. Guo et al. reported that SNHG16 promoted the proliferation and invasion of lung adenocarcinoma cells via splicing of let-7a-5p [16]. Similarly, Yu et al. showed the involvement of SNHG16 in the development of non-small-cell lung cancer development [17]. In other studies, SNHG16 has been shown to promote proliferation of lung cancer via miR-520/VEGF axis [18] and USP21/YY1 axis [19]. However, the role of lncRNA SNHG16 in lung cancer via modulation of ALDH2 expression has not been studied and was thus the objective of the present study.

2. Materials and Methods

2.1. Tissue Specimen and Cell Lines. Clinical specimens comprising of normal and malignant lung tissues were obtained from a total of 30 patients after surgical resection without chemo- or radiotherapy application at Henan Cancer Hospital. The tissues were collected from the patients after informed consent. This study was approved by the Ethical Committee of Henan Cancer Hospital under approval number HCH-63/2019. The pathological staging of the lung cancer tissues was performed by the hospital pathologists. The characteristics of the patients are listed in Table 1. All the clinical specimens were stored at -80°C until experimental use. Four lung cancer cell lines (A427, A549, HCC827, and SK-LU-1) and a normal lung cell line (MRC5) were obtained from the American Type Culture Collection. All the cell lines were cultured using DMEM (Gibco) medium at 37°C with 5% CO₂ concentration. Humidified incubator was used for maintenance of the cell lines.

2.2. Transfection. The transfection of cell lines was carried out through Lipofectamine 2000 (Thermo Fisher Scientific)–based method following the manufacturer’s guidelines. The small interfering RNA (siRNA) constructs of SNHG16 (si-SNGH16) and ALDH2 (si-ALDH2) along with its negative control (si-NC) were purchased from Ribobio Co., Ltd (Guangzhou, China). Mammalian overexpression vector, pcDNA3.1, was used for generating the overexpression construct of ALDH2.

2.3. Expression Analysis. To extract total RNA from tissues and cell lines, the samples were processed through TRIzol reagent (Thermo Fisher Scientific)–based method as per the manufacturer protocol. The RNA was reverse transcribed to synthesize first-strand cDNA with the help of PrimeScript 1st strand cDNA synthesis kit (Takara Bio). The SYBR Green PCR mix (Thermo Fisher Scientific) was used to perform real-time PCR (RT-PCR) on QuantStudio 5.0TM RT-PCR system (Thermo Fisher Scientific) to analyze the relative gene expression levels of SNHG16 and ALDH2. The 2⁻ddCt method was used for determining the relative expression values. Actin and GAPDH genes were used as an internal expression control in RT-PCR study. The nucleotide sequences of the primers used in the study are listed in Table 2.

2.4. Cell Viability Assay. The transfected A549 and SK-LU-1 cancer cells were added to 96-well microtiter plates with cellular density of 5,000 cells/well. The cells were cultured for 0, 12, 24, 48, and 96 h at 37°C. Afterwards, the wells were inoculated with MTT reagent (Thermo Fisher Scientific) at final concentration of 5 mg/mL culture medium, and incubation at 37°C was prolonged for 4 h. Then, 250 µL of DMSO were added to each well for dissolving the formazan precipitate, and finally the absorbance was recorded per sample at 570 nm. Three replicas were kept for each experimental sample.

2.5. Colony Formation Assay. The colony forming ability of A549 and SK-LU-1 cells after transfection with suitable constructs was determined by plating 500 cells/well (in a 6-well dish) in their regular media for about 12 days. Thereafter, the cells were stained with 0.5% crystal violet (in methanol) for 5 minutes. Following staining, the cells were washed in water, and the plates were dried overnight. Colonies with more than 50 cells were counted as a clone.

2.6. Cell Apoptosis Assays. The cancer cells were propagated in 96-well plates at 2 × 10⁵ cells/well. Afterwards, the cell
clusters were transfected with suitable constructs and then incubated for 24 h at 37°C. The cells were then harvested, fixed in 70% ethanol for 25 min at room temperature, washed three times with PBS, and subsequently treated with 0.3% Triton X-100 for 10 min for permeabilization. DAPI solution was used to stain the cells. The stained cells were dark incubated for 15 min and PBS washed. Finally, the DAPI signals were investigated through Cytation 5 Cell Imaging Multi-Mode Reader (BioTek, VT).

The apoptosis of transfected cancer cells was determined using Annexin V-FITC/PI apoptosis detection kit (BD Biosciences) as per manufacturer protocol. In brief, binding buffer was used for resuspending the transfected cells which were then stained with 15 μL annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI). Finally, flow cytometry was performed to determine the percentage of apoptotic cells.

2.7. Transwell Assay. A 24-well Transwell plate fitted without or with Matrigel, respectively, was used to analyze the migration and invasion of the transfected A549 and SK-LU-1 lung cancer cells transfected with si-NC or si-SNHG16. The cells were placed in the upper chamber of the Transwell plate, and the lower chamber was added with DMEM growth medium only. Following 24-h incubation at 37°C, the cells invading the lower chamber were fixed with methanol and then stained with 0.1% crystal violet. Lastly, the cells were examined under the light microscope (100×),

Table 2: List of primers used in the study.

| Primer | Direction | Sequence                  |
|-------|-----------|---------------------------|
| SNHG16| Forward   | 5'-GCAGAATGCCATGGTTTCCC-3' |
|       | Reverse   | 5'-GGACAGCTGGCAAGAGACTT-3' |
| ALDH2 | Forward   | 5'-GTTGGCTGTAGGAATCTGTCA-3' |
|       | Reverse   | 5'-AGGGAAGAGGAAACTCCTGA-3' |
| β-Actin| Forward   | 5'-CCTGGATAGC AACGTAC-3'   |
|       | Reverse   | 5'-CACCTTCTCACAATGAGCT-3'  |
| GADPH | Forward   | 5'-TCTCTGCTCCTCCTGTTC-3'   |
|       | Reverse   | 5'-GGTTGAGCAGGGTACTTTATTGA-3' |

Figure 1: LncRNA-SNHG2 has significant upregulation in lung cancer. Expression of SNHG2 in (a) normal and cancerous lung tissues, (b) clinical tissues comprising of different pathological stages of lung cancer, and (c) normal lung cell line (MRC5) and lung cancer cell lines (A427, A549, HCC827, and SK-LU-1) as determined by qRT-PCR. The gene expression study was performed using three replicates (⁎P < 0.05).
Figure 2: Continued.
photographs were taken, and randomly selected microscopic fields were used to determine the percentage of migration and invasion of cancer cells.

2.8. Wound Healing Assay. Transfected A549 and SK-LU-1 cells were cultured to obtain 90% confluency. A wound was created by scraping the cells using a P200 pipette tip, and images were captured immediately (0 h) and after 24 h. Migration of cells was assessed by observing the width of the wounds.

2.9. In Silico Target Analyses and Dual Luciferase Assay. In silico analyses were performed using LncRRIsearch software (http://rtools.cbr.cj/LncRRIsearch/detail.cgi) and VARNA: Visualization Applet for RNA software (http://varna.iri.fr/) to predict the interaction between SNHG16 and ALDH16. In silico analyses were performed using LncRRIsearch software (http://rtools.cbr.cj/LncRRIsearch/detail.cgi) and VARNA: Visualization Applet for RNA software (http://varna.iri.fr/) to predict the interaction between SNHG16 and ALDH16. The dual luciferase reporter assay was performed to confirm the in silico results. The A549 lung cancer cells were cotransfected with overexpression construct of SNHG16 (pcDNA-SNHG16) or control vector (pcDNA3.1) and luciferase reporter construct carrying 3′-UTR fragment of ALDH2 either in native (WT) or mutated state (MUT). The luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega) using Renilla luciferase gene as control of luciferase activity.

2.10. Western Blotting. The A549 and SK-LU-1 cancer cells stably transfected with si-SNHG16 or si-NC were lysed using the RIPA lysis and extraction buffer (Thermo Fisher Scientific) to extract total cellular proteins. After total protein concentration estimation, equal protein counts were separated using SDS-PAGE and then blotted to PVDF membranes. The protein bands were visualized through chemiluminescence following the treatment with specific primary and secondary antibodies. The western blotting study was normalized using the human β-actin protein.

2.11. In Vivo Study. Around 5-week-old BALB/c nude mice were used to create xenograft tumors in vivo by transplanting A549 lung cancer cells. 103 to 104 A549 lung cancer cells were suspended in Matrigel (BD Biosciences, USA) and then injected into the right flank mice, subcutaneously. After 2 weeks of the cell implantation, the mice were intraperitoneally administered with si-SNHG16 or negative control. Tumor volume was monitored every third day continuously for 3 weeks. After 3 weeks, the mice were euthanized, and the tumor weight was estimated. The 10% paraformaldehyde was used for fixing the tumors to be used for further investigation. The experimental use of animals was approved by the Institutional Ethics Committee. Standard institutional guidelines and scientific regulations were strictly followed for the experimental usage of animals.

2.12. Hematoxylin and Eosin (H&E) Staining and Immunohistochemical Staining. Formalin-fixed tumor tissues from nude mice were embedded in paraffin and cut into thin sections. The tissue sections were subsequently subjected to staining with H&E using standard procedures. For immunohistochemical staining, tissue sections were dewaxed and subsequently rehydrated in graded ethanol. Microwave heating in sodium citrate buffer (pH 6.0) was carried out for antigen retrieval. The sections were immersed in 3% H2O2 for 10 min to block endogenous peroxidase activity and subsequently subjected to incubation with primary antibodies at 4°C overnight. After washing, the sections were incubated with HRP-conjugated secondary antibody at room temperature for 1 h, and reactive products were visualized by staining with 3,3′-diaminobenzidene.
DAB). The images were obtained under a microscope (Olympus, Japan) with appropriate magnification.

2.13. Statistical Analysis. The final values represent the mean ± standard deviation (SD) determined using three replications per experimental setup. One-way ANOVA or Student’s t-test was performed using GraphPad Prism 7.0 software for statistical analysis. The P-value at <0.05 was taken as the measure of statistically significant difference.

3. Results

3.1. Transcriptional Upregulation of SNHG16 in Lung Cancer. The results revealed the expression of SNHG16 gene expression was significantly (P < 0.05) higher in lung cancer tissues in comparison to the normal lung tissues (Figure 1(a)). Further, SNHG16 expression was found to be enhancing with the progression of each pathological stage of lung cancer (Figure 1(b)). The lung cancer cell lines (A427, A549, HCC827, and SK-LU-1) were also found to exhibit significantly (P < 0.05) higher SNHG16 expression relative to the normal lung cell line (MRC5) (Figure 1(c)).

Next the clinical relevance of SNHG16 expression and clinico-pathological features of the patients were studied. For this, the samples were divided into two groups based on their average expression of SNHG16; a high expression group, and a low expression group. It was found that SNHG16 expression was positively associated with lymph node metastasis, distant metastasis, and clinical stage (Table 1). Collectively, these findings indicated a possible regulatory role of SNHG16 in lung cancer.

3.2. Decline in Cell Viability under SNHG16 Downregulation. To understand the growth regulatory role of SNHG16 in lung cancer, lung cancer cell lines A549 and SK-LU-1 were transfected with si-SNHG16, and downregulation of SNHG16 was confirmed from the transfected cancer cells in comparison to the negative control cells (Figure 2(a)). The cancer cells were then processed for viability assessment using MTT assay, and it was shown that cancer cells exhibited significant (P < 0.05) decline in their viabilities under SNHG16 knockdown (Figure 2(b)). Knockdown of SNHG16 also caused considerable decrease in the colony formation potential of A549 and SK-LU-1 cells (Figure 2(c)). Next,
A549 and SK-LU-1 lung cancer cells transfected with si-SNHG-16 along with the respective negative control cancer cells were analyzed for nuclear morphology using DAPI staining. Both the cell lines exhibited apoptotic signs and showed loss of nuclear integrity (Figure 2(d)). To further confirm the induction of apoptosis in cancer cells under SNHG16 silencing, flow cytometric analysis was used. The percentage of apoptotic cells was comparatively higher under SNHG16 silencing (Figure 2(e)). From the western blotting, it was found that Bax protein concentration was considerably higher, while reverse was true for Bcl-2 under SNHG16 knockdown (Figure 2(f)). Together, the results are indicative of apoptosis mediated loss of lung cancer cell viability under SNHG16 gene silencing.

3.3. SNHG16 Silencing Inhibits Cell Migration and Invasion. The migration and invasion of the lung cancer cell lines, A549, and SK-LU-1 transfected with si-NC or si-SNHG16 were estimated through wound healing and Transwell chamber assays. The results of wound healing assay showed that knockdown of SNHG16 prevented the migration of A549 and SK-LU-1 cells (Figure 3(a)). These results were also supported by the results of Transwell assay which showed that silencing of SNHG16 decreased the migration of A549 and SKL-1 cells by around 45% (Figure 3(b)). Similarly, the invasion of the A549 and SKLU-1 cells was inhibited by around 50% (Figure 3(c)).

3.4. Interaction of SNHG16 with ALDH2 in Lung Cancer. The interaction of SNHG16 with ALDH2 was predicted through in silico analyses (Figures 4(a) and 4(b)). The in silico results were confirmed through dual-luciferase reporter assay where the interaction of SNHG16 with UTR of ALDH2 was confirmed from the decline of luciferase activity (Figure 4(c)). For further confirmation, we evaluated the expression of ALDH2 in lung cancer tissues and cell lines by qRT-PCR. It was found that the expression pattern of ALDH2 in lung cancer tissues was also found to be downregulated in human ALDH2 in lung cancer cell lines (Figure 4(d)). IHC analysis also showed considerable downregulation of ALDH2 in lung cancer tissues (Figure 4(e)). Moreover, the expression of ALDH2 decreased with advancement of the disease (Figure 4(f)). The expression of ALDH2 was also downregulated in human lung cancer cell lines (Figure 4(g)). However, overexpression of SNHG16 in A549 lung cancer cells increased the protein concentration of ALDH2 in lung cancer cells (Figure 4(h)). Additionally, SNH16 was found to be negatively correlated (r = −0.812) with ALDH2 expression, and the upregulation of SNH16 was manifested as transcriptional repression of ALDH2 suggesting the modulation of molecular role of SNHG16 through ALDH2 targeting in lung cancer.

3.5. Exertion of SNHG16 Role through ALDH2 in Lung Cancer. To confirm whether SNHG16 exerted its growth regulatory role in lung cancer through negative regulation of ALDH2, the overexpression of ALDH2 was performed in lung cancer cells. The lung cancer cell viabilities and colony formation was found to be significantly (P < 0.05) lower under ALDH2 overexpression (Figures 5(a) and 5(b)). Cancer cells overexpressing ALDH2 were induced for apoptosis (Figures 5(c) and 5(d)). Further, inhibition of ALDH2 could avoid the inhibitory effects of SNHG16 knockdown on viability and colony formation of A549 cells (Figures 5(e) and 5(f)). Consistently, the lung cancer cells did not show apoptotic features when cotransfected with silencing constructs of ALDH2 and SNHG16 (Figures 5(g) and 5(h)). The results thus confirmed the modulation of growth regulatory effects of SNHG16 in lung cancer through ALDH2 posttranscriptional downregulation.

3.6. Rescue Effects of ALDH2 Silencing on Migration and Invasion of Lung Cancer Cells under SNHG16 Knockdown. The effects of ALDH2 silencing were evaluated on the migration and invasion of A549 cells under SNHG16 knockdown by wound healing and Transwell assays. It was found that migration and invasion of A549 cells was significantly (P < 0.05) inhibited under SNHG16 knockdown. However, silencing of ALDH2 could prevent the inhibitory effects of SNHG16 on the migration and invasion of A549 cells (Figures 6(a)–6(c)).

3.7. Silencing of SNHG16 Restrained In Vivo Tumor Growth and Upregulated ALDH2. The investigation of tumor regulatory role SNHG16 was carried out using the mice xenograft models. The mice tumor xenografts were constituted by injecting the animals with A549 cancer cell suspension, subcutaneously. Subsequently, the intraperitoneal (IP) injections were given carrying si-SNHG16 or its negative control, si-NC. The administration of mice with si-SNHG16 inhibited the xenograft tumor growth, significantly (Figure 7(a)). The SNHG16 silencing was reconfirmed by qRT-PCR (Figure 7(b)). H&E staining showed smaller and more unified nuclei in the si-SNHG16 tumors (Figure 7(c)). IHC staining showed mice tumors injected with si-SNHG16 constructs exhibited considerable upregulation of ALDH2 (Figure 7(d)). The mice tumor volume was monitored every 3rd day after cancer cell implantation. The average mice tumor volume and weight administered with si-SNHG16 were significantly (P < 0.05) lower than the si-NC control-treated mice (Figures 7(e) and 7(f)). The results are thus suggestive that the silencing of SNHG16 suppresses the tumor growth in vivo. Additionally, western blot analysis showed that expression of Bax and cleavage of caspase-3 was increased, while the expression of Bcl-2 was decreased upon SNHG16 knockdown (Figure 7(g)) indicative of apoptosis.

4. Discussion

At the global level, lung cancer is the leading cause of cancer-related deaths [1–3]. Out of the total lung cancer cases detected per year, more than 85% patients die within the same year [20]. One of the major factors responsible for extremely high mortality of lung cancer is that most of the patients are diagnosed with the malignancy only at stage III or IV [21]. In the present study, the gene expression levels of lncRNA-SNHG16 were found to be correlating with the advancement of lung cancer pathogenesis and thus might
Figure 4: SNHG16 interacted and repressed ALDH2 in lung cancer, posttranscriptionally. (a) In silico analysis for prediction of SNHG16 and ALDH2 interaction in lung cancer through LncRRIsearch software; (b) in silico analysis for prediction of SNHG16 and ALDH2 interaction in lung cancer through VARNA: Visualization Applet for RNA software; (c) dual luciferase assay showing interaction between SNHG16 and ALDH2; (d) relative gene expression of ALDH2 in normal and cancerous lung tissues; (e) IHC analysis showing expression of ALDH2 in three pairs (I, II, and III) of normal and cancerous tissues; (f) relative gene expression of ALDH2 at different pathological stages of lung cancer; (g) relative gene expression of ALDH2 in normal lung cell line (MRC5) and lung cancer cell lines (A427, A549, HCC827, and SK-LU-1); (h) relative protein expression of ALDH2 in A549 cancer cells transfected with si-SNHG16 or si-NC. Each experiment was performed with three replicates (*P < 0.05).
Figure 5: ALDH2 modulated the regulatory role of lncRNA-SNHG16 in lung cancer. (a) Estimation of viabilities of A549 cancer cells by MTT assay at different culture stages, transfected with pcDNA-ALDH2 or control vector pcDNA3.1 (NC); (b) colony formation of A549 cancer cells transfected with pcDNA-ALDH2 or control vector pcDNA3.1 (NC); (c) DAPI staining of A549 cancer cells transfected with pcDNA-ALDH2 or NC; (d) flow cytometry for analysis of apoptosis of A549 cancer cells transfected with pcDNA-ALDH2 or NC; (e) estimation of viabilities of A549 cancer cells by MTT assay at different culture stages, transfected with si-SNHG16, pcDNA-ALDH2, or si-SNHG16 plus si-ALDH2; (f) colony formation of A549 cancer cells transfected with si-SNHG16, pcDNA-ALDH2, or si-SNHG16 plus si-ALDH2; (g) DAPI staining of A549 cancer cells transfected with si-SNHG16, si-NC, or si-SNHG16 plus si-ALDH2; (h) flow cytometry for analysis of apoptosis of A549 cancer cells transfected with si-SNHG16, si-NC, or si-SNHG16 plus si-ALDH2. Three replicates were used for performing the experiments (*P < 0.05) (arrows depict apoptotic cells).
be utilized as a vital prognostic tool against the same as has been also proposed for SNHG16 in other human cancers [22, 23]. Further, the distant metastasis is believed to make it exceedingly difficult to combat the malignancy of human lung cancer rendering the current therapeutic measures ineffective [24]. Thus, to devise more efficient and novel anti-cancer strategies against the lung cancer, it is very crucial to understand the mechanics of this deadly disorder more thoroughly with exploration of various molecular links underlying its growth and progression. The present study showed that lncRNA-SNHG16 regulates the growth of lung cancer cells, and its transcriptional silencing effectively reduced the in vitro cancer cell growth. The tumor-suppressive effect of SNHG16 knockdown was shown to be resulting from the induction of apoptosis in lung cancer cells which further confirms its established role as reported by the previous research investigations [25, 26]. The key finding of the present of the present study was the elucidation of molecular interaction of SNHG16 with human aldehyde dehydrogenase 2 (ALDH2) at posttranscriptional level. The study revealed that the latter is negatively regulated by SNHG16 at posttranscriptional level as proven from luciferase assay and both the gene and protein expression studies of ALDH2. The study made it lucid that repression of ALDH2 at posttranscriptional level by SNHG16 was responsible for exerting the growth regulatory role of latter in lung cancer. The tumor regulatory role of SNHG16 was also evident from the in vivo mice tumorigenesis study. The results suggested that the in vivo tumor growth was reduced through ALDH2 upregulation. The repression of ALDH2 in lung cancer and its tumor promoting role has been worked out previously [27]. It was found that reduced ALDH2 levels impair the

Figure 6: Rescue effect of ALDH silencing on invasion of lung cancer cells under SNHG16 knockdown: (a) wound healing assay showing migration in A549 cells transfected with si-NC, si-SNHG16, and si-SNHG16 + si-ALDH; (b) Transwell assay showing cell migration of A549 cells transfected with si-NC, si-SNHG16, and si-SNHG16 + si-ALDH; (c) Transwell cell invasion of A549 cells transfected with si-NC, si-SNHG16, and si-SNHG16 + si-ALDH. Three replicates were used for performing the experiments (*P < 0.05).
Figure 7: SNHG16 knockdown suppresses in vivo mice tumor xenograft growth. (a) Analysis of tumor size from the mice administered with si-SNHG16 or si-NC; (b) expression of SNHG16 in mice tumors administered with si-SNHG16 or si-NC; (c) H&E staining of si-NC and si-SNHG16 tumors; (d) IHC showing expression of ALDH2 protein in si-SNHG16 or si-NC tumors; (e) analysis of tumor volume at indicated study stages from the mice administered with si-SNHG16 or si-NC; (f) average weight of si-SNHG16 or si-NC tumors; (g) western blotting showing expression of Bax, Bcl-2, and cleaved caspase-3 in si-NC or si-SNHG16 tumors (*P < 0.05).
pathway of detoxification of acetaldehyde to nontoxic acetic acid and proved how it caused DNA damage and promoted the growth and development of lung cancer [27]. Hence, the present research work is an extension to the established research results about the role of ALDH2 in lung cancer and disclosed the mechanism accounting for its repression in lung cancer to promote the advancement of this deadly disease. Taken together, the results of current study suggest prognostic and therapeutic utility of lncRNA-SNHG16 and its down-stream target ALDH2 against human lung cancer. Nonetheless, it needs to be elucidated whether SNHG16 directly regulates the expression of ALDH2 or via involvement of microRNA. Additionally, findings need to be confirmed by study involving large number of clinical specimen.

5. Conclusion
Collectively, the results of current study are supportive of the growth regulatory role of SNHG16 in lung cancer. The study highlights the prognostic and therapeutic role of SNHG16 in lung cancer and advocates the targeting of SNHG16/ALDH2 axis as potential and novel anticancer strategy against the devastating malignancy of human lung cancer.

Data Availability
The data regarding this paper is available on request to the author.

Conflicts of Interest
The authors declare that there no conflicts of interest.

References
[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015.
[2] B. C. Bade and C. S. Cruz, "Lung cancer 2020: epidemiology, etiology, and prevention," Clinics in Chest Medicine, vol. 41, no. 1, pp. 1–24, 2020.
[3] C. Muhass, P. A. Kumar, and D. Raja, "Etiological factors for the development of lung cancer in non-smokers: an overview," International Journal of Pharmacy and Pharmaceutical Sciences, vol. 11, pp. 10–16, 2019.
[4] F. F. Costa, "Non-coding RNAs: meet thy masters," BioEssays, vol. 32, no. 7, pp. 599–608, 2010.
[5] M. Kellis, B. Wold, M. P. Snyder et al., "Defining functional DNA elements in the human genome," Proceedings of the National Academy of Sciences, vol. 111, no. 17, pp. 6131–6138, 2014.
[6] M. Guttmann and J. L. Rinn, "Modular regulatory principles of large non-coding RNAs," Nature, vol. 482, no. 7385, pp. 339–346, 2012.
[7] H. S. Chiu, S. Somvanshi, E. Patel et al., "Pan-cancer analysis of lncRNA regulation supports their targeting of cancer genes in each tumor context," Cell Reports, vol. 23, no. 1, pp. 297–312.e12, 2018.
[8] X. Huo, S. Han, G. Wu et al., "Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells," Molecular Cancer, vol. 16, no. 1, pp. 1–10, 2017.
[9] M. Sun, F. Q. Nie, Z. X. Wang, and W. De, “Involvement of lncRNA dysregulation in gastric cancer,” Histology and Histopathology, vol. 31, pp. 33–39, 2015.
[10] K. Li, W. Guo, Z. Li et al., “ALDH2 repression promotes lung tumor progression via accumulated acetaldehyde and DNA damage,” Neoplasia, vol. 21, no. 6, pp. 602–614, 2019.
[11] G. Loewen, J. Jayawickramarajah, Y. Zhuo, and B. Shan, “Functions of lncRNA HOTAIR in lung cancer,” Journal of Hematology & Oncology, vol. 7, no. 1, p. 90, 2014.
[12] Y. R. Yang, S. Z. Zang, C. L. Zhong, Y. X. Li, S. S. Zhao, and X. J. Feng, “Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 10, pp. 6929–6935, 2014.
[13] L. L. Christensen, K. True, M. P. Hamilton et al., “SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism,” Molecular Oncology, vol. 10, no. 8, pp. 1266–1282, 2016.
[14] H. Zhu, Y. Zeng, C. C. Zhou, and W. Ye, “SNHG16/miR-216-5p/ZEB1 signal pathway contributes to the tumorigenesis of cervical cancer cells,” Archives of Biochemistry and Biophysics, vol. 637, pp. 1–8, 2018.
[15] W. Han, X. Du, M. Liu, J. Wang, L. Sun, and Y. Li, “Increased expression of long non-coding RNA SNHG16 correlates with tumor progression and poor prognosis in non-small cell lung cancer,” International Journal of Biological Macromolecules, vol. 121, pp. 270–278, 2019.
[16] Y. Guo, H. Zhen, W. Chen, Y. Sun, K. Li, and E. Feng, “Long non-coding RNA SNHG16 promotes cell proliferation and invasion in lung adenocarcinoma via sponging let-7a-5p,” Minerva Chirurgica, vol. 74, no. 6, pp. 509–511, 2019.
[17] L. Yu, D. Chen, and J. Song, “LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-5p,” Thorac Cancer, vol. 11, no. 3, pp. 603–611, 2020.
[18] L. Chen, C. H. Qu, Y. Chen, Y. Wang, J. J. Zhao, and M. Zhang, “LncRNA SNHG16 drives proliferation, migration, and invasion of lung cancer cell through modulation of miR-520/VEGF axis,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 18, pp. 9522–9531, 2020.
[19] P. Xu, H. Xiao, Q. Yang et al., “The USP21/YY1/SNHG16 axis contributes to tumor proliferation, migration, and invasion of non-small cell lung cancer,” Experimental & Molecular Medicine, vol. 52, no. 1, pp. 41–55, 2020.
[20] C. Zappa and S. A. Mousa, “Non-small cell lung cancer: current treatment and future advances,” Translational Lung Cancer Research, vol. 5, no. 3, pp. 288–300, 2016.
[21] T. Wang, R. A. Nelson, A. Bogardus, and F. W. Grannis Jr., “Five-year lung cancer survival: which advanced stage non-small cell lung cancer patients attain long-term survival?,” Cancer, vol. 116, no. 6, pp. 1518–1525, 2010.
[22] X. Cao, J. Xu, and D. Yue, “LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer,” Cancer Gene Therapy, vol. 25, no. 1-2, pp. 10–17, 2018.
[23] H. Chen, M. Li, and P. Huang, “LncRNA SNHG16 promotes hepatocellular carcinoma proliferation, migration and invasion by regulating miR-186 expression,” Journal of Cancer, vol. 10, no. 15, pp. 3571–3581, 2019.
[24] T. W. Mollet, C. A. Garcia, and G. Koester, “skin metastases from lung cancer,” *Dermatology Online Journal*, vol. 15, no. 5, p. 5, 2009.

[25] S. Liu, W. Zhang, K. Liu, and Y. Liu, “LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p,” *Biomedicine & Pharmacotherapy*, vol. 114, p. 108862, 2019.

[26] X. S. Yang, G. X. Wang, and L. Luo, “Long non-coding RNA SNHG16 promotes cell growth and metastasis in ovarian cancer,” *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 3, pp. 616–622, 2018.

[27] Y. Li, Z. Yin, J. Fan, S. Zhang, and W. Yang, “The roles of exosomal miRNAs and lncRNAs in lung diseases,” *Signal Transduction and Targeted Therapy*, vol. 4, no. 1, pp. 1–12, 2019.